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Highly active antiretroviral therapy (HAART) has been very efficient in reducing 
the rate of mortality of human immunodeficiency virus type 1 (HIV-1) infected 
patients.  However, resistance to clinically used drugs inevitably develops and 
impairs the potency of these drugs.  There is also no vaccine available to prevent 
the spread of the virus.  Our collaborators, Dr. Shuzo Matsushita and his 
colleagues have developed a monoclonal antibody, KD-247, that is currently in 
Phase Ib clinical trials for the treatment of HIV-1 infections.  KD-247 blocks virus 
entry into host cells by binding to the V3 loop of the surface glycoprotein of HIV.  
It is the first humanized antibody shown to neutralize a wide range of subtype B 
HIV viruses (Matsushita et al. Hum. Antibodies, 14, 81) and to prevent HIV 
infection in cell culture and in a chimpanzee model (Eda et al. J. Virol., 80, 5563).  
KD-247 reacts exclusively with subtype B viruses (Eda et al. J. Virol., 80, 5552).  
In order to understand the molecular basis of this specificity we have solved the 
crystal structure of KD-247 at 1.5 Å resolution, the highest resolution structure for 
any humanized antibody reported to date.  The present structure reveals in 
atomic detail the molecular boundaries of a pocket formed by the antigen-binding 
region of the antibody.  Molecular docking experiments of a pre-existing structure 
of the V3-loop target at the presumed binding pocket on KD-247 suggest 
possible molecular interactions involved in HIV resistance to KD-247 and clade B 
specificity.  A G314E V3 loop mutation that has been reported to confer 
resistance to KD-247 (Yoshimura et al., AIDS 20, 2065) appears to result in 
steric interactions between the tip of the V3 loop and residues of the heavy chain 
of KD-247.  Further, Arg315, a residue critical for clade B specificity, appears to 
form extensive interactions with multiple residues of KD-247.   Analysis of these 
interactions has provided insights into the design of second-generation 
antibodies with broader subtype specificity and improved ability to evade 
resistance mutations.  This work is a product of collaborations between the 
University of Missouri and researchers at Kumamoto University, an academic 
institution in Japan, and the Chemo-Sero-Therapeutic Research Institute, an 
industrial partner in Japan, working to commercialize the antibody and further its 
progress in clinical trials. 
